ABSTRACT
No disponible
Subject(s)
Adult , Humans , Breast Neoplasms , Breast Feeding/trends , Lactation/physiology , Fluorodeoxyglucose F18 , Positron-Emission Tomography/instrumentation , Positron-Emission Tomography/methods , Tomography, Emission-Computed , Lymphatic Metastasis/diagnosis , Lymphatic Metastasis/pathology , Neoplasm MetastasisABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Neuroendocrine Tumors/complications , Neuroendocrine Tumors/therapy , Neuroendocrine Tumors , Biopsy/methods , Vagina/pathology , Vagina , Positron-Emission Tomography/instrumentation , Positron-Emission Tomography/methods , Neurosecretory SystemsABSTRACT
Objective. There is still no consensus about whether to perform PET/CT to detect carcinoma in paraneoplastic neurological syndromes (PNS) in patients with or without antibodies. The aim of this study is to determine the diagnostic accuracy of PET/CT and antibodies in patients with PNS. Material and Methods. A retrospective study was conducted on patients with clinically suspected PNS between 2008 and 2013. The association between histopathological findings, paraneoplastic antibodies, and PET/CT findings were evaluated. Sensitivity and specificity for the detection of underlying malignancy were calculated for PET/CT and paraneoplastic antibodies. Results. A total of 42 patients were analyzed. Of these 42 patients, 32 (75%) had a classical PNS, 6 (14%) had positive PET/CT findings, and 34 were tested for the presence of antibodies (anti-Hu Ab, anti-Yo Ab, and anti-Ri Ab). Twenty one of 34 patients had positive antibodies. Of the 6 patients with positive PET/CT findings, 6 had positive histopathological results. Among 21 patients with positive biomarkers, carcinoma was confirmed only in 5 patients. One patient with negative antibodies, but positive PET/CT findings, was diagnosed with a tumor. Gastric carcinoma was detected in 1 patient with negative PET/CT findings and antibodies during follow-up. Based on the results, PET/CT was found to have 85.71% sensitivity, 100% specificity, 100% positive and 97.22% negative predictive values in the detection of tumors. Conclusion. PET/CT has a certain diagnostic accuracy for detecting underlying malignancy in patients with PNS, regardless of the presence of paraneoplastic antibodies (AU)
Objetivo. No hay un criterio unánime para realizar PET/TC en la detección de carcinoma en pacientes de síndrome neurológico paraneoplásico (PNS), con o sin anticuerpos. Nuestro objetivo es buscar la utilidad diagnóstica de la PET/TC y los anticuerpos en pacientes con PNS. Material y métodos. Se examinaron retrospectivamente los pacientes con sospecha clínica de PNS estudiados entre 2008 y 2013. Se evaluó la asociación entre los resultados histopatológicos, los anticuerpos y los resultados de la PET/TC. Se calcularon la sensibilidad y la especificidad de la PET/TC y de los anticuerpos paraneoplásicos para la detección de malignidad. Resultados. Se analizaron un total de 42 pacientes. De ellos 32 pacientes (el 75%) tenían un PNS clásico. A todos se les había realizado PET/TC y 6 (el 14%) tuvieron resultados positivos. Se determinó la presencia de anticuerpos en 34 pacientes (anticuerpos anti-Hu, anticuerpos anti-Yo y anticuerpos anti-Ri). Veintiuno de los cuales dieron positivo. Los 6 pacientes con resultados PET/TC positivos tuvieron resultados histopatológicos positivos. Entre los 21 pacientes con biomarcadores positivos, el carcinoma se confirmó solo en 5 pacientes. A un paciente con resultado negativo para anticuerpos, pero positivo en la PET/TC, se le diagnosticó un tumor. Se detectó carcinoma gástrico en un paciente con resultados negativos en la PET/TC y anticuerpos en el periodo de seguimiento. Según los resultados, se comprobó que la PET/TC tiene un 85,71% de sensibilidad, un 100% de especificidad, con valor predictivo positivo de 100% y valor predictivo negativo de 97,22% en la detección de tumores. Conclusión. La PET/TC tiene un cierto grado de exactitud diagnóstica para detectar malignidad subyacente en pacientes con PNS, sin importar la presencia de anticuerpos paraneoplásicos (AU)
Subject(s)
Humans , Male , Female , Paraneoplastic Syndromes , Paraneoplastic Syndromes, Nervous System , Positron-Emission Tomography , Adenocarcinoma , Immunohistochemistry/methods , Immunohistochemistry , Retrospective Studies , Sensitivity and Specificity , Carcinoma , Nuclear Medicine/methodsABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Radiopharmaceuticals , Neuroendocrine Tumors , Pancreatic Neoplasms , Octreotide , False Positive ReactionsABSTRACT
No disponible
Subject(s)
Humans , Lymphatic Metastasis/pathology , Fluorodeoxyglucose F18 , Positron-Emission Tomography/methods , Positron Emission Tomography Computed Tomography/methods , Soft Tissue Neoplasms , Diagnostic ImagingABSTRACT
No disponible
Subject(s)
Humans , Male , Child, Preschool , Neoplasms, Neuroepithelial , Positron-Emission Tomography/methods , Tuberculosis, Meningeal , Diagnosis, DifferentialSubject(s)
Humans , Female , Middle Aged , Neoplasms, Multiple Primary/complications , Neoplasms, Multiple Primary , Fluorodeoxyglucose F18 , Positron-Emission Tomography/instrumentation , Positron-Emission Tomography/methods , Somatostatin , Somatostatin/isolation & purification , Receptors, Somatostatin/analysis , Receptors, Somatostatin/isolation & purificationABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Meningioma , Fluorodeoxyglucose F18 , Positron Emission Tomography Computed Tomography/instrumentation , Positron Emission Tomography Computed Tomography/methods , Positron Emission Tomography Computed Tomography , Contrast Media , Positron Emission Tomography Computed Tomography/standards , Positron Emission Tomography Computed Tomography/trendsABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Fluorodeoxyglucose F18 , Positron Emission Tomography Computed Tomography/instrumentation , Positron Emission Tomography Computed Tomography/methods , Positron Emission Tomography Computed Tomography , Lymphoma, B-Cell , Lymphoma, Large B-Cell, Diffuse , Positron Emission Tomography Computed Tomography/standards , Positron Emission Tomography Computed Tomography/trends , Leukemia, Lymphocytic, Chronic, B-CellABSTRACT
La fibrosis retroperitoneal es una enfermedad poco común caracterizada por fibrosis inflamatoria típicamente en el área de la aorta abdominal y las arterias iliacas. El análogo de la glucosa F18 -fluorodeoxiglucosa puede usarse para obtener imágenes de la actividad celular inflamatoria de manera no invasiva por PET. En este informe, estudiamos la utilidad de FDG PET/TAC en la evaluación de la actividad de la enfermedad y respuesta al tratamiento de la fibrosis retroperitoneal(AU)
Retroperitoneal fibrosis is an uncommon disease characterized by inflammatory fibrosis typically surrounding abdominal aorta and iliac arteries. The glucose analogue F18-fluorodeoxyglucose can be used to image inflammatory cell activity non-invasively by PET. In this report we investigated the usefulness of the FDG PET/CT in the disease activity and therapy response evaluation of retroperitoneal fibrosis(AU)